COMP <GO>
ITT vs TMO // EV/EBITDA & P/E VALUATION
ITT Inc. Common Stock (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ITT 7
— TMO 6
▲ EV/EBITDA & P/E VALUATION LEADER: ITT
LAST: $198.50 (-2.00%) • MKT CAP: $18.11B
valuation
20.2x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ITT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ITT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.40% | 41.00% | -5.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 9.30% | +9.60 | ITT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.2x | 30.4x | -10.20 | ITT | /valuation <GO> |
| Free Cash Flow Yield | 2.09% | 2.40% | -0.31 | TMO | /fcf-yield <GO> |
| Operating Margin | 17.40% | 17.40% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 15.10% | -2.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 8.50% | 3.90% | +4.60 | ITT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.61% | 0.24% | +0.37 | ITT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.93 | 4.50 | +2.43 | ITT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | ITT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 59.1 | -9.93 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 36.3x | -1.80 | ITT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.11B | $262.22B | -$244.11B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ITT REV | TMO REV | ITT GROSS % | TMO GROSS % | ITT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.94B | $44.56B | 35.4% | 44.0% | $369.3M | $6.29B |
| FY 2024 | $3.63B | $42.88B | 34.4% | 44.0% | $418.9M | $7.27B |
| FY 2023 | $3.28B | $42.86B | 44.0% | 44.0% | $313.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ITT // BETA 0.89
TMO // BETA 0.94